Article Text

Download PDFPDF

403 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-OV50/GOG-329/INNOVATE-3
  1. Ignace B Vergote1,
  2. Jalid Sehouli2,
  3. Roldano Fossati3,
  4. Robert Coleman4,
  5. Bradley Monk5,
  6. Larry Copeland6 and
  7. David O’malley7
  1. 1Leuven Cancer Institute, Leuven, Belgium; Leuven Cancer Institute, Leuven, Belgium; Gynaecological Oncology
  2. 2Charité Universitätsmedizin Berlin; Klinik für Gynäkologie
  3. 3Irccs-Istituto DI Ricerche Farmacologiche, Milan
  4. 4MD Anderson Cancer Center University of Texas
  5. 5Arizona Oncology US Oncology Network
  6. 6The James Cancer Hospital; Ohio State University Comprehensive Cancer Center
  7. 7Ohio State University Comprehensive Cancer Center


Introduction/Background Tumor Treating Fields (TTFields) are a non-invasive, antimitotic cancer therapy. The Phase 2 INNOVATE study demonstrated safety of TTFields/weekly paclitaxel in 31 PROC (platinum-resistant ovarian cancer) patients (Vergote Gyn Onc 2018); efficacy: median PFS 8.9 months, 25% partial response,71% clinical benefit and 61% 1-year survival rate. This phase 3 ENGOT-ov50/GOG-329/INNOVATE-3 study [NCT03940196] investigates TTFields plus weekly paclitaxel in PROC patients.

Methodology Patients (N=540) will have PROC (RECIST V1.1) within 6 months of last platinum therapy with maximum of 2–5 prior lines of systemic therapy, ECOG 0–1 and no peripheral neuropathy >grade1. Patients with primary refractory disease will be excluded. Patients will be randomized 1:1 to weekly paclitaxel alone or weekly paclitaxel (starting of dose 80 mg/m2 weekly for 8 weeks, and then on Days 1, 8, and 15 for subsequent 28-day cycle ) plus TTFields (200 kHz for 18 hours/day and continued if no progression in the abdominal or pelvic regions (‘in-field region’) per RECIST V1.1. Clinical follow-up will be performed q4w, with radiological follow-up (CT or MRI scans of the abdomen and chest) q8w. The primary endpoint is overall survival. Secondary endpoints: PFS, objective response rate, AEs, and quality of life (EORTC QLQ-C30 with QLQ-OV28). Sample size (n=540) will detect an increase in median OS from 12 to 16 months (HR 0.75). Data Monitoring Committee (DMC) meeting (March 2020) concluded that data to-date showed no safety issues and recommended trial continuation.

Results TiP N/A

Conclusion TiP N/A

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.